This Article Full Text (OnlineFirst PDF) All Versions of this Article: 1087057108319642v1 13/6/515    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Du, W. Articles by Schneider, E. M. Search for Related Content PubMed PubMed Citation Articles by Du, W. Articles by Schneider, E. M. Social Bookmarking                         What's this?

A Direct Immunoassay Assessment of Streptavidin- and N-Hydroxysuccinimide-Modified Biochips in Validation of Serological TNF Responses in Hemophagocytic Lymphohistiocytosis

Universitaetsklinikum Ulm

^* To whom correspondence should be addressed. E-mail: weidong.du{at}uni-ulm.de.

	Abstract

The authors report 2 biochip platforms on gold manufactured by either nanoscale biotinylated self-assembled architectures to streptavidin surface or proteins containing free NH₂ groups to N-hydroxysuccinimide (NHS)–activated surfaces and investigated the potential application of tumor necrosis factor– (TNF) serodiagnosis of hemophagocytic lymphohistiocytosis (HLH). Interactions of TNF antigen and TNF antibody on the biochips were optimized using an indirect immunofluorescence method. Variation coefficients were 1.87% to 4.56% on the streptavidin biochip and 5.03% to 8.64% on the NHS biochip. The correlation coefficients (r) in TNF and TNF antibody assays in HLH patients between the 2 biochip formats were 0.9623 and 0.9386 and the concordance frequencies were 92.2% and 96.1%, respectively. To detect plasma TNF-receptor complexes (TNFR1 and R2) in HLH, a biochip assay strategy was developed. Plasma levels of TNF, TNF antibody, and TNF-receptor complexes (TNFR1 and R2) were detected in plasmas from 42 HLH cases using streptavidin biochips. Frequencies of the biomarkers in the plasmas were 40.5% (17/42) for TNF, 30.9% (13/42) for TNF antibody, 28.6% (12/42) for TNF–receptor 1 complex, and 26.1% (11/42) for TNF–receptor 2 complex, respectively. The streptavidin biochip format was more sensitive than the NHS surface and was demonstrated to be a valuable tool to identify individual biomarker molecules and molecular complexes in sera and cell lysates and to track therapeutic progress of patients. (Journal of Biomolecular Screening XXXX:xx-xx)

First published on June 19, 2008, doi:10.1177/1087057108319642

Journal of Biomolecular Screening 2008;13:515.

A more recent version of this article appeared on July 1, 2008


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?